Ki16425 [355025-24-0]
Referência HY-13285-5mg
Tamanho : 5mg
Marca : MedChemExpress
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK. Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
Ki16425 Chemical Structure
CAS No. : 355025-24-0
This product is a controlled substance and not for sale in your territory.
Based on 8 publication(s) in Google Scholar
Voir tous les produits spécifiques à Isoform LPL Receptor:
Description |
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK[1][2]. Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells[3]. |
IC50 & Target |
Ki: 0.34 μM (LPA1), 0.93 μM (LPA3), 6.5 μM (LPA2)[1] |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
Ki16425 (10 μM; 1.5 hours; HEK293A cells) treatment blocks LPA-induced dephosphorylation of YAP/TAZ in HEK293A cells. Ki16425 partially inhibits the ability of serum to repress YAP/TAZ phosphorylation, particularly at low serum concentrations (0.2%)[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[3]
|
||||||||||||
In Vivo |
Ki16425 (Debio 0719) (1-30 mg/kg; i.p.; at 30 min prior to LPA injection) inhibits LPA-induced neuropathic pain-like behaviors[4]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||
Masse moléculaire |
474.96 |
||||||||||||
Formule |
C23H23ClN2O5S |
||||||||||||
CAS No. |
355025-24-0 |
||||||||||||
Appearance |
Solid |
||||||||||||
Color |
White to off-white |
||||||||||||
SMILES |
ClC1=C(C=CC=C1)C(C)OC(NC2=C(ON=C2C)C3=CC=C(C=C3)CSCCC(O)=O)=O |
||||||||||||
Livraison | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Stockage |
|
||||||||||||
Solvant et solubilité |
In Vitro:
DMSO : ≥ 100 mg/mL (210.54 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Pureté et documentation |
Purity: 98.11% |
||||||||||||
Références |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 2.1054 mL | 10.5272 mL | 21.0544 mL | 52.6360 mL |
5 mM | 0.4211 mL | 2.1054 mL | 4.2109 mL | 10.5272 mL | |
10 mM | 0.2105 mL | 1.0527 mL | 2.1054 mL | 5.2636 mL | |
15 mM | 0.1404 mL | 0.7018 mL | 1.4036 mL | 3.5091 mL | |
20 mM | 0.1053 mL | 0.5264 mL | 1.0527 mL | 2.6318 mL | |
25 mM | 0.0842 mL | 0.4211 mL | 0.8422 mL | 2.1054 mL | |
30 mM | 0.0702 mL | 0.3509 mL | 0.7018 mL | 1.7545 mL | |
40 mM | 0.0526 mL | 0.2632 mL | 0.5264 mL | 1.3159 mL | |
50 mM | 0.0421 mL | 0.2105 mL | 0.4211 mL | 1.0527 mL | |
60 mM | 0.0351 mL | 0.1755 mL | 0.3509 mL | 0.8773 mL | |
80 mM | 0.0263 mL | 0.1316 mL | 0.2632 mL | 0.6580 mL | |
100 mM | 0.0211 mL | 0.1053 mL | 0.2105 mL | 0.5264 mL |
Ki16425 Related Classifications
- GPCR/G Protein
- LPL Receptor